<?xml version="1.0" encoding="utf-8"?><!DOCTYPE article PUBLIC "-//ES//DTD journal article DTD version 5.0.2//EN//XML" "art502.dtd" [<!ENTITY gr1 SYSTEM "gr1" NDATA IMAGE><!ENTITY gr2a SYSTEM "gr2a" NDATA IMAGE><!ENTITY gr2bc SYSTEM "gr2bc" NDATA IMAGE><!ENTITY gr3 SYSTEM "gr3" NDATA IMAGE><!ENTITY gr4 SYSTEM "gr4" NDATA IMAGE>]><article docsubtype="sco" xml:lang="en"> <ce:floats xmlns:ce="http://www.elsevier.com/xml/common/dtd"> <ce:figure id="fig1"> <ce:label>Fig. 1</ce:label> <ce:caption> <ce:simple-para>11&#x3B2;-HSD1 mRNA expression and reductase activity were induced by LPS in J774.1 macrophages. J774.1 cells (1<ce:hsp sp="0.25"/>&#xD7;<ce:hsp sp="0.25"/>10<ce:sup>6</ce:sup><ce:hsp sp="0.25"/>cells/ml, not-confluent) were treated with LPS (10&#x2013;10<ce:sup>3</ce:sup><ce:hsp sp="0.25"/>ng/ml, 12 or 24<ce:hsp sp="0.25"/>h). (A) Level of mRNA for 11&#x3B2;-HSD1 was determined by real-time PCR. Level of each mRNA was normalized to that of 18S rRNA. (B) (left): 11&#x3B2;-HSD1 reductase activity (expressed as conversion ability of cortisone to cortisol) and (right): 11&#x3B2;-HSD1 dehydrogenase activity (expressed as conversion ability of cortisol to cortisone) were assessed in the media of J774.1 cells treated with 10<ce:hsp sp="0.25"/>ng/ml LPS for 24<ce:hsp sp="0.25"/>h. Reference corresponds to [<ce:sup loc="pre">3</ce:sup>H] cortisone or [<ce:sup loc="pre">3</ce:sup>H] cortisol used as a size marker. A representative autoradiograph of thin-layer chromatography (TLC) in 11&#x3B2;-HSD activity assay (upper) and quantification ( lower). Intensities of signals at cortisol and cortisone correspond to the enzyme activity of reductase and dehydrogenase, respectively. U.D.; under detectable. Data are expressed as mean<ce:hsp sp="0.25"/>&#xB1;<ce:hsp sp="0.25"/>S.E.M. of triplicate experiments. <ce:sup loc="pre">&#x2217;</ce:sup><ce:italic>P</ce:italic><ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.05 vs. vehicle (V) treated group.</ce:simple-para> </ce:caption> <ce:link locator="gr1"/> </ce:figure> <ce:figure id="fig2"> <ce:label>Fig. 2</ce:label> <ce:caption> <ce:simple-para>11&#x3B2;-HSD1 activity assay for validation of 11&#x3B2;-HSD1 inhibitors. (A) Microsome fraction 11&#x3B2;-HSD1 activity assay: inhibitor A (0.01&#x2013;100<ce:hsp sp="0.25"/>&#x3BC;M), inhibitor B (0.1&#x2013;100<ce:hsp sp="0.25"/>&#x3BC;M), CBX, carbenoxolone (0.01&#x2013;10<ce:hsp sp="0.25"/>&#x3BC;M). The <ce:italic>x</ce:italic>-axis shows the log concentration of each inhibitor and the <ce:italic>y</ce:italic>-axis shows log<ce:hsp sp="0.12"/>% inhibition of 11&#x3B2;-HSD1 activity compared to control. (B) Intact cell assay for 11&#x3B2;-HSD1 reductase activity. J774.1 cells were incubated for 24<ce:hsp sp="0.25"/>h in serum-free RPMI 1640, adding 250<ce:hsp sp="0.25"/>nM of cortisone with tritium labeled cortisone (left): a representative autoradiograph of TLC in 11&#x3B2;-HSD activity assay and (right): quantification of 11&#x3B2;-HSD activities. Intensities of signals at cortisol correspond to the enzyme activity of reductase. The <ce:italic>y</ce:italic>-axis shows the percentage of 11&#x3B2;-HSD1 reductase activity compared to LPS (10<ce:hsp sp="0.25"/>mg/ml) treated cells per se. Treatment of inhibitor A (10<ce:hsp sp="0.25"/>&#x3BC;M), inhibitor B (100<ce:hsp sp="0.25"/>&#x3BC;M), and CBX (100<ce:hsp sp="0.25"/>&#x3BC;M) substantially reduced 11&#x3B2;-HSD1 activity in J774.1 cells (inhibitor A and inhibitor B as mentioned in Section <ce:cross-ref refid="sec1">2</ce:cross-ref>).</ce:simple-para> </ce:caption> <ce:link locator="gr2"/> </ce:figure> <ce:figure id="fig3"> <ce:label>Fig. 3</ce:label> <ce:caption> <ce:simple-para>Pharmacological inhibition of 11&#x3B2;-HSD1 considerably reduced IL-1 &#x3B2;, TNF-&#x3B1; or MCP-1 expression in and secretion from LPS-activated J774.1 macrophages. Effect of pharmacological inhibition of 11&#x3B2;-HSD1 on (A) IL-1&#x3B2;, (B) TNF-&#x3B1; and (C) MCP-1 mRNA in and secretion from LPS-activated J774.1 macrophages: J774.1 cells were activated by LPS (10<ce:hsp sp="0.25"/>ng/ml) and co-treated with inhibitor A (10<ce:hsp sp="0.25"/>&#x3BC;M), inhibitor B (100<ce:hsp sp="0.25"/>&#x3BC;M) or CBX (100<ce:hsp sp="0.25"/>&#x3BC;M) for 24<ce:hsp sp="0.25"/>h. (upper); mRNA for IL-1&#x3B2;, TNF-&#x3B1; and MCP-1 determined by real-time PCR. Level of each mRNA was normalized to that of 18S rRNA and expressed as a relative value vs. control (lower). Concentrations of IL-1&#x3B2;, TNF-&#x3B1; and MCP-1 in the media measured by ELISA. Data are expressed as means<ce:hsp sp="0.25"/>&#xB1;<ce:hsp sp="0.25"/>S.E.M. of triplicate experiments. <ce:sup loc="pre">&#x2217;&#x2217;</ce:sup><ce:italic>P</ce:italic><ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.01 vs. vehicle (V) treated group. <ce:sup loc="pre">#</ce:sup><ce:italic>P</ce:italic><ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.05, <ce:sup loc="pre">##</ce:sup><ce:italic>P</ce:italic><ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.01 vs. LPS-treated cells.</ce:simple-para> </ce:caption> <ce:link locator="gr3"/> </ce:figure> <ce:table frame="topbot" id="tbl1" rowsep="0" colsep="0"> <ce:label>Table 1</ce:label> <ce:caption> <ce:simple-para>Sequences of TaqMan primers and probes</ce:simple-para> </ce:caption> <tgroup cols="4"> <colspec colname="col1" align="left"/> <colspec colname="col2" align="left"/> <colspec colname="col3" align="left"/> <colspec colname="col4" align="left"/> <thead> <row rowsep="1" valign="top"> <entry>Gene</entry> <entry>GenBank accession no.</entry> <entry>Probe (FAM-5&#x2032;<ce:hsp sp="0.25"/>&#x2192;<ce:hsp sp="0.25"/>3&#x2032;-TAMRA)</entry> <entry>Primer (5&#x2032;<ce:hsp sp="0.25"/>&#x2192;<ce:hsp sp="0.25"/>3&#x2032;)</entry> </row> </thead> <tbody> <row valign="top"> <entry morerows="1"> <ce:italic>Hsd11b1</ce:italic> </entry> <entry morerows="1"> <ce:inter-ref xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="genbank:NM008288" xlink:type="simple">NM008288</ce:inter-ref> </entry> <entry morerows="1"> <ce:monospace>TCCGAGTTCAAGGCAGCGAGACACTACC</ce:monospace> </entry> <entry>f <ce:monospace>CCAGGTCGGAGGAAGGTCTC</ce:monospace></entry> </row> <row valign="top"> <entry>r <ce:monospace>CCAGCAATGTAGTGAGCAGAGG</ce:monospace></entry> </row> <row valign="top"> <entry morerows="1"> <ce:italic>Hsd11b2</ce:italic> </entry> <entry morerows="1"> <ce:inter-ref xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="genbank:NM008289" xlink:type="simple">NM008289</ce:inter-ref> </entry> <entry morerows="1"> <ce:monospace>TCAAGCCTGGCTGCTCCAAGACAG</ce:monospace> </entry> <entry>f <ce:monospace>TCCCTGGGGTATCAAGGTCAG</ce:monospace></entry> </row> <row valign="top"> <entry>r <ce:monospace>CTCCCAGAGGTTCACATTAGTCAC</ce:monospace></entry> </row> <row valign="top"> <entry morerows="1"> <ce:italic>Il1b</ce:italic> </entry> <entry morerows="1"> <ce:inter-ref xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="genbank:NM008361" xlink:type="simple">NM008361</ce:inter-ref> </entry> <entry morerows="1"> <ce:monospace>CATGGCACATTCTGTTCAAAGAGAGCCTG</ce:monospace> </entry> <entry>f <ce:monospace>TCGCTCAGGGTCACAAAGAAA</ce:monospace></entry> </row> <row valign="top"> <entry>r <ce:monospace>CCATCAGAGGCAAGGAGGAA</ce:monospace></entry> </row> <row valign="top"> <entry morerows="1"> <ce:italic>Tnf</ce:italic> </entry> <entry morerows="1"> <ce:inter-ref xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="genbank:NM013693" xlink:type="simple">NM013693</ce:inter-ref> </entry> <entry morerows="1"> <ce:monospace>CCCGACTACGTGCTCCTCACCCA</ce:monospace> </entry> <entry>f <ce:monospace>TCTCTTCAAGGGACAAGGCTG</ce:monospace></entry> </row> <row valign="top"> <entry>r <ce:monospace>ATAGCAAATCGGCTGACGGT</ce:monospace></entry> </row> <row valign="top"> <entry morerows="1"> <ce:italic>Ccl2</ce:italic> </entry> <entry morerows="1"> <ce:inter-ref xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="genbank:NM011333" xlink:type="simple">NM011333</ce:inter-ref> </entry> <entry morerows="1"> <ce:monospace>CCCCACTCACCTGCTGCTACTCATTCA</ce:monospace> </entry> <entry>f <ce:monospace>TTGGCTCAGCCAGATGCA</ce:monospace></entry> </row> <row valign="top"> <entry>r <ce:monospace>CCAGCCTACTCATTGGGATCA</ce:monospace></entry> </row> <row valign="top"> <entry morerows="1"> <ce:italic>Il1r1</ce:italic> </entry> <entry morerows="1"> <ce:inter-ref xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="genbank:NM008362" xlink:type="simple">NM008362</ce:inter-ref> </entry> <entry morerows="1"> <ce:monospace>CCTGACTTCAAGAATTACCTCATCGG</ce:monospace> </entry> <entry>f <ce:monospace>GCATGTGCAGTTAATATACC</ce:monospace></entry> </row> <row valign="top"> <entry>r <ce:monospace>CAATTGTAGCCGTGAGGATG</ce:monospace></entry> </row> <row valign="top"> <entry morerows="1"> <ce:italic>Tnfrsf1a</ce:italic> </entry> <entry morerows="1"> <ce:inter-ref xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="genbank:NM011609" xlink:type="simple">NM011609</ce:inter-ref> </entry> <entry morerows="1"> <ce:monospace>AGTGAGTGCGTCCCTTGCAGCC</ce:monospace> </entry> <entry>f <ce:monospace>GCAGGGTTCTTTCTGAGAG</ce:monospace></entry> </row> <row valign="top"> <entry>r <ce:monospace>GGCACAACTTCATACACTCC</ce:monospace></entry> </row> <row valign="top"> <entry morerows="1"> <ce:italic>Ccr2</ce:italic> </entry> <entry morerows="1"> <ce:inter-ref xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="genbank:NM009915" xlink:type="simple">NM009915</ce:inter-ref> </entry> <entry morerows="1"> <ce:monospace>CTCTGTCACCTGCATGGCCTGGTCT</ce:monospace> </entry> <entry>f <ce:monospace>ATGAGTAACTGTGTGATTGACAAGCA</ce:monospace></entry> </row> <row valign="top"> <entry>r <ce:monospace>GCAGCAGTGTGTCATTCCAAGA</ce:monospace></entry> </row> <row valign="top"> <entry morerows="1"> <ce:italic>Nr3c1</ce:italic> </entry> <entry morerows="1"> <ce:inter-ref xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="genbank:NM008173" xlink:type="simple">NM008173</ce:inter-ref> </entry> <entry morerows="1"> <ce:monospace>CCTGCTATGCTTTGCTCCTGATCTGATT</ce:monospace> </entry> <entry>f <ce:monospace>ATCATACAGACAAGCAAGTGGAA</ce:monospace></entry> </row> <row valign="top"> <entry>r <ce:monospace>AGGGTAGAGTCATTCTCTGCTC</ce:monospace></entry> </row> <row valign="top"> <entry morerows="1"> <ce:italic>Tlr4</ce:italic> </entry> <entry morerows="1"> <ce:inter-ref xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="genbank:NM021297" xlink:type="simple">NM021297</ce:inter-ref> </entry> <entry morerows="1"> <ce:monospace>CATGCCTTGTCTTCAATTGTTTCAA</ce:monospace> </entry> <entry>f <ce:monospace>CTTCAGTGGCTGGATTTATC</ce:monospace></entry> </row> <row valign="top"> <entry>r <ce:monospace>GAGGTGGTGTAAGCCATG</ce:monospace></entry> </row> </tbody> </tgroup> <ce:legend> <ce:simple-para>Forward primers are designated by f and reverse primers by r.</ce:simple-para> <ce:simple-para><ce:italic>Abbreviations: FAM, 6-carboxyfluorescein; TAMRA, 6-carboxytetramethylrhodamine. Hsd11b1</ce:italic>, hydroxysteroid 11-beta dehydrogenase 1; <ce:italic>Hsd11b2</ce:italic>, hydroxysteroid 11-beta dehydrogenase 2; <ce:italic>l1b</ce:italic>, interleukin 1 beta; <ce:italic>Tnf</ce:italic>, tumor necrosis factor; <ce:italic>Ccl2</ce:italic> (=monocyte chemoattractant protein:MCP-1); chemokine (C&#x2013;C motif) ligand 2, <ce:italic>Il1r1</ce:italic>; interleukin 1 receptor, type I, <ce:italic>Tnfrsf1a</ce:italic> (=TNFR1), tumor necrosis factor receptor superfamily member 1a; Ccr2, chemokine (C&#x2013;C motif) receptor 2; <ce:italic>Nr3c1</ce:italic> (=glucocorcoid receptor, GR); nuclear receptor subfamily 3, group C, member 1; <ce:italic>Tlr4</ce:italic>, toll-like receptor 4.</ce:simple-para> </ce:legend> </ce:table> </ce:floats> <head> <ce:title xmlns:ce="http://www.elsevier.com/xml/common/dtd">Augmentation of 11&#x3B2;-hydroxysteroid dehydrogenase type 1 in LPS-activated J774.1 macrophages &#x2013; Role of 11&#x3B2;-HSD1 in pro-inflammatory properties in macrophages</ce:title> <ce:presented xmlns:ce="http://www.elsevier.com/xml/common/dtd">Edited by Beat Imhof</ce:presented> <ce:author-group xmlns:ce="http://www.elsevier.com/xml/common/dtd"> <ce:author> <ce:given-name>Takako</ce:given-name> <ce:surname>Ishii</ce:surname> </ce:author> <ce:author> <ce:given-name>Hiroaki</ce:given-name> <ce:surname>Masuzaki</ce:surname> <ce:cross-ref refid="cor1"> <ce:sup>&#x204E;</ce:sup> </ce:cross-ref> <ce:e-address type="email">hiroaki@kuhp.kyoto-u.ac.jp</ce:e-address> </ce:author> <ce:author> <ce:given-name>Tomohiro</ce:given-name> <ce:surname>Tanaka</ce:surname> </ce:author> <ce:author> <ce:given-name>Naoki</ce:given-name> <ce:surname>Arai</ce:surname> </ce:author> <ce:author> <ce:given-name>Shintaro</ce:given-name> <ce:surname>Yasue</ce:surname> </ce:author> <ce:author> <ce:given-name>Nozomi</ce:given-name> <ce:surname>Kobayashi</ce:surname> </ce:author> <ce:author> <ce:given-name>Tsutomu</ce:given-name> <ce:surname>Tomita</ce:surname> </ce:author> <ce:author> <ce:given-name>Michio</ce:given-name> <ce:surname>Noguchi</ce:surname> </ce:author> <ce:author> <ce:given-name>Junji</ce:given-name> <ce:surname>Fujikura</ce:surname> </ce:author> <ce:author> <ce:given-name>Ken</ce:given-name> <ce:surname>Ebihara</ce:surname> </ce:author> <ce:author> <ce:given-name>Kiminori</ce:given-name> <ce:surname>Hosoda</ce:surname> </ce:author> <ce:author> <ce:given-name>Kazuwa</ce:given-name> <ce:surname>Nakao</ce:surname> </ce:author> <ce:affiliation> <ce:textfn>Division of Endocrinology and Metabolism, Department of Medicine and Clinical Science, Kyoto University Graduate School of Medicine, 54, Shogoin Kawaharacho, Sakyoku, Kyoto 606-8507, Japan</ce:textfn> </ce:affiliation> <ce:correspondence id="cor1"> <ce:label>&#x204E;</ce:label> <ce:text>Corresponding author. Fax: +81 75 771 9452.</ce:text> </ce:correspondence> </ce:author-group> <ce:abstract xmlns:ce="http://www.elsevier.com/xml/common/dtd" class="author" xml:lang="en"> <ce:section-title>Abstract</ce:section-title> <ce:abstract-sec> <ce:simple-para>Macrophage infiltration in obese adipose tissue provokes local inflammation and insulin resistance. Evidence has accumulated that activation of 11&#x3B2;-HSD1 in adipocytes is critically involved in dysfunction of adipose tissue. However, the potential role of 11&#x3B2;-HSD1 in macrophages still remains unclear. We here demonstrate that a murine macrophage cell line, J774.1 cells expressed 11&#x3B2;-HSD1 mRNA and reductase activity, both of which were augmented by lipopolysaccharide (LPS)-induced cell activation. Three kinds of pharmacological inhibition of 11&#x3B2;-HSD1 in LPS-treated macrophages significantly suppressed the expression and secretion of interleukin 1&#x3B2;, tumor necrosis factor &#x3B1; or monocyte chemoattractant protein 1, thereby highlighting a novel role of 11&#x3B2;-HSD1 in pro-inflammatory properties of activated macrophages.</ce:simple-para> </ce:abstract-sec> </ce:abstract> <ce:keywords xmlns:ce="http://www.elsevier.com/xml/common/dtd" class="abr"> <ce:section-title>Abbreviations</ce:section-title> <ce:keyword> <ce:text>11&#x3B2;-HSD1</ce:text> <ce:keyword> <ce:text>11&#x3B2;-hydroxysteroid dehydrogenase type 1</ce:text> </ce:keyword> </ce:keyword> <ce:keyword> <ce:text>11&#x3B2;-HSD2</ce:text> <ce:keyword> <ce:text>11&#x3B2;-hydroxysteroid dehydrogenase type 2</ce:text> </ce:keyword> </ce:keyword> <ce:keyword> <ce:text>LPS</ce:text> <ce:keyword> <ce:text>lipopolysaccharide</ce:text> </ce:keyword> </ce:keyword> <ce:keyword> <ce:text>TLR4</ce:text> <ce:keyword> <ce:text>toll-like receptor 4</ce:text> </ce:keyword> </ce:keyword> <ce:keyword> <ce:text>IL-1&#x3B2;</ce:text> <ce:keyword> <ce:text>interleukin 1&#x3B2;</ce:text> </ce:keyword> </ce:keyword> <ce:keyword> <ce:text>IL1R1</ce:text> <ce:keyword> <ce:text>interleukin 1 receptor type 1</ce:text> </ce:keyword> </ce:keyword> <ce:keyword> <ce:text>TNF-&#x3B1;</ce:text> <ce:keyword> <ce:text>tumor necrosis factor &#x3B1;</ce:text> </ce:keyword> </ce:keyword> <ce:keyword> <ce:text>TNFR1</ce:text> <ce:keyword> <ce:text>tumor necrosis factor receptor type 1</ce:text> </ce:keyword> </ce:keyword> <ce:keyword> <ce:text>MCP-1</ce:text> <ce:keyword> <ce:text>monocyte chemoattractant protein 1</ce:text> </ce:keyword> </ce:keyword> <ce:keyword> <ce:text>CCR2</ce:text> <ce:keyword> <ce:text>chemokine (C&#x2013;C motif) receptor 2</ce:text> </ce:keyword> </ce:keyword> <ce:keyword> <ce:text>GR</ce:text> <ce:keyword> <ce:text>glucocorticoid receptor</ce:text> </ce:keyword> </ce:keyword> <ce:keyword> <ce:text>SVF</ce:text> <ce:keyword> <ce:text>stromal-vascular fraction</ce:text> </ce:keyword> </ce:keyword> <ce:keyword> <ce:text>inhibitor A</ce:text> <ce:keyword> <ce:text>3-(1-adamantyl)-5,6,7,8,9,10-hexahydro[1,2,4]triazolo[4,3-&#x3B1;]azocine trifluoroacetate salt</ce:text> </ce:keyword> </ce:keyword> <ce:keyword> <ce:text>inhibitor B(BVT-3498), 2,4,6-trichloro-<ce:italic>N</ce:italic>-(5,5-dimethyl-7-oxo-4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)benzenesulfonamide</ce:text> </ce:keyword> <ce:keyword> <ce:text>CBX</ce:text> <ce:keyword> <ce:text>carbenoxolone</ce:text> </ce:keyword> </ce:keyword> <ce:keyword> <ce:text>DEX</ce:text> <ce:keyword> <ce:text>dexamethasone</ce:text> </ce:keyword> </ce:keyword> </ce:keywords> <ce:keywords xmlns:ce="http://www.elsevier.com/xml/common/dtd" class="keyword"> <ce:section-title>Keywords</ce:section-title> <ce:keyword> <ce:text>11&#x3B2;-HSD1</ce:text> </ce:keyword> <ce:keyword> <ce:text>Macrophage</ce:text> </ce:keyword> <ce:keyword> <ce:text>Inflammation</ce:text> </ce:keyword> <ce:keyword> <ce:text>Metabolic syndrome</ce:text> </ce:keyword> <ce:keyword> <ce:text>Inhibitor</ce:text> </ce:keyword> <ce:keyword> <ce:text>Adipocyte</ce:text> </ce:keyword> </ce:keywords> </head> <body> <ce:sections xmlns:ce="http://www.elsevier.com/xml/common/dtd"> <ce:section> <ce:label>1</ce:label> <ce:section-title>Introduction</ce:section-title> <ce:para>Functional abnormalities in adipose tissue have been implicated in the central pathophysiology of the metabolic syndrome <ce:cross-ref refid="bib1">[1]</ce:cross-ref>. Glucocorticoids regulate adipocyte differentiation, function and distribution, and in excess, cause visceral fat obesity and convergence of metabolic diseases <ce:cross-ref refid="bib2">[2]</ce:cross-ref>. Two iso-enzymes of 11&#x3B2;-HSD, 11&#x3B2;-HSD1 and 11&#x3B2;-HSD2 catalyze the interconversion between hormonally active cortisol and inactive cortisone within cells. 11&#x3B2;-HSD1 is abundantly expressed in adipose tissue and liver <ce:cross-refs refid="bib2 bib3">[2,3]</ce:cross-refs> and reactivates cortisol from cortisone (oxo-reductase) <ce:cross-ref refid="bib4">[4]</ce:cross-ref>. Previous reports have demonstrated that 11&#x3B2;-HSD1 predominates in adipocytes compared to 11&#x3B2;-HSD2 <ce:cross-ref refid="bib2">[2]</ce:cross-ref>, which inactivates cortisol to cortisone (dehydrogenase). Targeted overexpression of 11&#x3B2;-HSD1 selectively in adipose tissue in mice exemplified metabolic derangements including visceral fat obesity, insulin resistance, dyslipidemia and hypertension <ce:cross-refs refid="bib5 bib6">[5,6]</ce:cross-refs>. Conversely, systemic 11&#x3B2;-HSD1 knockouts as well as adipose-specific 11&#x3B2;-HSD2 overexpressors are completely protected against metabolic diseases under overnutrition <ce:cross-refs refid="bib7 bib8 bib9">[7&#x2013;9]</ce:cross-refs>. These data suggest that increased level of adipose 11&#x3B2;-HSD1 plays a crucial role in dysfunction of adipose tissue and resultant metabolic disorders.</ce:para> <ce:para>On the other hand, recent studies have demonstrated that infiltration of macrophages in obese adipose tissue provokes local and systemic inflammation and insulin resistance <ce:cross-refs refid="bib10 bib11 bib12">[10&#x2013;12]</ce:cross-refs>. It has been shown that matured adipocytes abundantly express 11&#x3B2;-HSD1 which is critically involved in dysfunction of adipose tissue <ce:cross-refs refid="bib2 bib5">[2,5]</ce:cross-refs>. However, the potential role of 11&#x3B2;-HSD1 in macrophages remains largely unclear. In this context, we explored the expression and regulation of 11&#x3B2;-HSD1 in a murine reticular cell sarcoma-derived J774.1 macrophages <ce:cross-ref refid="bib13">[13]</ce:cross-ref>. To our knowledge, this is the first to demonstrate that 11&#x3B2;-HSD1 is critically involved in pro-inflammatory properties of activated macrophages.</ce:para> </ce:section> <ce:section role="materials-methods" id="sec1"> <ce:label>2</ce:label> <ce:section-title>Materials and methods</ce:section-title> <ce:section> <ce:label>2.1</ce:label> <ce:section-title>Reagents and chemicals</ce:section-title> <ce:para>All reagents were of analytical grade unless otherwise indicated. Carbenoxolone <ce:cross-refs refid="bib4 bib14 bib15">[4,14,15]</ce:cross-refs>, a non-selective inhibitor for 11&#x3B2;-HSD1 and 11&#x3B2;-HSD2 was obtained from Sigma (St. Louis, MO, USA). Recently-developed 11&#x3B2;-HSD1 selective inhibitors, 3-(1-adamantyl)-5,6,7,8,9,10-hexahydro[1,2,4] triazolo [4,3-&#x3B1;] azocine trifluoroacetate salt (WO03/065983, Merck Co., USA) (inhibitor A for short, unless otherwise indicated) <ce:cross-ref refid="bib16">[16]</ce:cross-ref> and 2,4,6-trichloro-<ce:italic>N</ce:italic>-(5,5-dimethyl-7-oxo-4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl) benzenesulfonamide (BVT-3498, Biovitrum, Sweden) (inhibitor B for short, unless otherwise indicated) <ce:cross-refs refid="bib17 bib18">[17,18]</ce:cross-refs> were synthesized according to the patent information.</ce:para> </ce:section> <ce:section> <ce:label>2.2</ce:label> <ce:section-title>Cell culture</ce:section-title> <ce:para>Mouse reticulum cell sarcoma-derived J774.1 cells <ce:cross-ref refid="bib13">[13]</ce:cross-ref> were obtained from Cell Resource Center for Biomedical Research Institute of Development, Aging and Cancer, Tohoku University, Japan. Cells were cultured in RPMI 1640 plus 10% heat-inactivated FBS at 37<ce:hsp sp="0.25"/>&#xB0;C in 5% CO<ce:inf>2</ce:inf>.</ce:para> </ce:section> <ce:section> <ce:label>2.3</ce:label> <ce:section-title>Quantitative real time PCR</ce:section-title> <ce:para>Total RNA was extracted using Trizol Reagent (Invitrogen, USA) and cDNA was synthesized using iScript&#x2122; cDNA Synthesis Kit (Bio-Rad, USA) according to the manufacturer&#x2019;s instruction. The sequence of probes and primers are summarized in <ce:cross-ref refid="tbl1">Table 1</ce:cross-ref><ce:float-anchor refid="tbl1"/>. Taqman PCR was performed using ABI Prism 7700 Sequence Detection System as instructed by the manufacture (Applied Biosystems, USA). Level of mRNA was normalized to those of 18S mRNA.</ce:para> </ce:section> <ce:section> <ce:label>2.4</ce:label> <ce:section-title>11&#x3B2;-HSD1 enzyme activity assay</ce:section-title> <ce:para>11&#x3B2;-HSD1 primarily acts as a reductase and reactivates cortisol from cortisone in viable cells. On the other hand, under some conditions such as tissue homogenate or microsome fraction, 11&#x3B2;-HSD1 acts as a dehydrogenase and inactivate cortisone to cortisol <ce:cross-ref refid="bib2">[2]</ce:cross-ref>. 11&#x3B2;-HSD1 reductase activity in intact cells was measured as reported <ce:cross-ref refid="bib2">[2]</ce:cross-ref>. Briefly, cells were incubated for 24<ce:hsp sp="0.25"/>h in serum-free RPMI 1640, adding 250<ce:hsp sp="0.25"/>nM cortisone including tritium labeled tracer [1,2-<ce:sup loc="pre">3</ce:sup>H]<ce:inf>2</ce:inf> cortisone for reductase activity and 250<ce:hsp sp="0.25"/>nM cortisol with [1,2,6,7-<ce:sup loc="pre">3</ce:sup>H]<ce:inf>4</ce:inf> cortisol for dehydrogenase activity. Cortisol and cortisone were extracted using ethyl acetate, evaporated and resuspended in ethanol, separated by thin-layer chromatography in chloroform:methanol (95:5) and quantified by autoradiography.</ce:para> <ce:para>To validate inhibitory potency of compounds against 11&#x3B2;-HSD1, using FreeStyle 293 cells transiently transfected with human 11&#x3B2;-HSD1, the enzyme activity assay was carried out with 20<ce:hsp sp="0.25"/>mM Tris&#x2013;HCl, pH 7.0, 50<ce:hsp sp="0.25"/>&#x3BC;M NADPH, 5<ce:hsp sp="0.25"/>&#x3BC;g protein of microsomal fraction, 300<ce:hsp sp="0.25"/>nM <ce:sup loc="pre">3</ce:sup>H-cortison for 2<ce:hsp sp="0.25"/>h. The reaction was stopped by 18&#x3B2;-Glycyrrhetinic acid. The labeled cortisol product was captured by mouse monoclonal anti-cortisol antibody, bound to SPA beads coated with protein A, and quantified in a scintillation counter.</ce:para> </ce:section> <ce:section> <ce:label>2.5</ce:label> <ce:section-title>Measurement of IL-1&#x3B2;, TNF-&#x3B1; and MCP-1 concentrations in cultured media</ce:section-title> <ce:para>Interleukin 1&#x3B2; (IL-1&#x3B2;), tumor necrosis factor &#x3B1; (TNF-&#x3B1;) and monocyte chemoattractant protein 1 (MCP-1) concentrations in J774.1 cell (1<ce:hsp sp="0.25"/>&#xD7;<ce:hsp sp="0.25"/>10<ce:sup>6</ce:sup><ce:hsp sp="0.25"/>cells/ml) cultured media were measured by enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturers instructions (R<ce:hsp sp="0.12"/>&amp;<ce:hsp sp="0.12"/>D Systems, USA).</ce:para> </ce:section> <ce:section> <ce:label>2.6</ce:label> <ce:section-title>Statistical analysis</ce:section-title> <ce:para>Data are expressed as the means<ce:hsp sp="0.25"/>&#xB1;<ce:hsp sp="0.25"/>S.E.M. of triplicate experiments. Data were analyzed using one-way analysis of variance (ANOVA), followed by Student&#x2019;s <ce:italic>t</ce:italic>-tests for each pair for multiple comparisons. Differences were considered significant if <ce:italic>P</ce:italic><ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.05.</ce:para> </ce:section> </ce:section> <ce:section> <ce:label>3</ce:label> <ce:section-title>Results</ce:section-title> <ce:section> <ce:label>3.1</ce:label> <ce:section-title>11&#x3B2;-HSD1 mRNA level and reductase activity were substantially increased in activated J774.1 macrophages</ce:section-title> <ce:para>Lipopolysaccharide (LPS) is a potent ligand for toll-like receptor (TLR) 4 and a representative activator of macrophages <ce:cross-refs refid="bib19 bib20">[19,20]</ce:cross-refs>. When J774.1 cells were treated with LPS (100<ce:hsp sp="0.25"/>ng/ml) for 24<ce:hsp sp="0.25"/>h, mRNA level of IL-1&#x3B2;, TNF-&#x3B1; and MCP-1 was markedly increased compared to control (approximately 1500-fold, 3-fold, 220-fold, respectively, <ce:italic>P</ce:italic><ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.01). LPS (100<ce:hsp sp="0.25"/>ng/ml, 24<ce:hsp sp="0.25"/>h) also substantially augmented 11&#x3B2;-HSD1 mRNA level in J774.1 macrophages (&#x223C;20-fold vs. control. <ce:italic>P</ce:italic><ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.01) (<ce:cross-ref refid="fig1">Fig. 1</ce:cross-ref><ce:float-anchor refid="fig1"/>A). 11&#x3B2;-HSD1 reductase activity was concomitantly augmented by LPS (100<ce:hsp sp="0.25"/>ng/ml) compared to LPS-free control (2.9<ce:hsp sp="0.25"/>&#xB1;<ce:hsp sp="0.25"/>1.2-fold vs. control. <ce:italic>P</ce:italic><ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.05) (<ce:cross-ref refid="fig1">Fig. 1</ce:cross-ref>B). Notably, 11&#x3B2;-HSD1 dehydrogenase activity was under-detectable not only at the basal but with LPS treatment (<ce:cross-ref refid="fig1">Fig. 1</ce:cross-ref>C).</ce:para> </ce:section> <ce:section> <ce:label>3.2</ce:label> <ce:section-title>Effect of pharmacological inhibition of 11&#x3B2;-HSD1 on inflammatory properties in J774.1 macrophages</ce:section-title> <ce:para>To explore the potential role of 11&#x3B2;-HSD1 in cytokine release from activated macrophages, we examined the effect of pharmacological inhibition of 11&#x3B2;-HSD1 on gene expression of LPS-treated J774.1 cells. In the present study, two kinds of 11&#x3B2;-HSD1 selective inhibitors: inhibitor A and inhibitor B were synthesized and employed (as mentioned in materials and methods). 11&#x3B2;-HSD1 and 11&#x3B2;-HSD2 non-selective inhibitor, carbenoxolone (CBX) was also utilized. Based on our data that 11&#x3B2;-HSD2 mRNA (data not shown) and corresponding enzyme activity (dehydrogenase) <ce:cross-refs refid="bib2 bib3">[2,3]</ce:cross-refs> were under detectable in J774.1 cells even with LPS treatment (<ce:cross-ref refid="fig1">Fig. 1</ce:cross-ref>), CBX was considered to act virtually as a specific inhibitor against 11&#x3B2;-HSD1.</ce:para> <ce:para>In the microsome fraction assay, we verified that inhibitor A (100<ce:hsp sp="0.25"/>&#x3BC;M), inhibitor B (100<ce:hsp sp="0.25"/>&#x3BC;M) and CBX (1<ce:hsp sp="0.25"/>&#x3BC;M), all potently inhibited 11&#x3B2;-HSD1 activity as little as 25% vs. control, respectively (<ce:cross-ref refid="fig2">Fig. 2</ce:cross-ref><ce:float-anchor refid="fig2"/>A). In J774.1 cells, treatment of inhibitor A (10<ce:hsp sp="0.25"/>&#x3BC;M), inhibitor B (100<ce:hsp sp="0.25"/>&#x3BC;M), and CBX (100<ce:hsp sp="0.25"/>&#x3BC;M) markedly inhibited 11&#x3B2;-HSD1 activity (48<ce:hsp sp="0.25"/>&#xB1;<ce:hsp sp="0.25"/>23% [<ce:italic>P</ce:italic><ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.05], 30<ce:hsp sp="0.25"/>&#xB1;<ce:hsp sp="0.25"/>1% [<ce:italic>P</ce:italic><ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.01], and 80<ce:hsp sp="0.25"/>&#xB1;<ce:hsp sp="0.25"/>7% [<ce:italic>P</ce:italic><ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.01] of reduction vs. LPS-treated cells, respectively), confirming that these compounds serve as potent inhibitors against 11&#x3B2;-HSD1 in J774.1 cells (<ce:cross-ref refid="fig2">Fig. 2</ce:cross-ref>B).</ce:para> <ce:para>Noteworthy is that treatment of J774.1 cells with inhibitor A (10<ce:hsp sp="0.25"/>&#x3BC;M), inhibitor B (100<ce:hsp sp="0.25"/>&#x3BC;M) and CBX (100<ce:hsp sp="0.25"/>&#x3BC;M) reduced IL-1&#x3B2; mRNA level (27<ce:hsp sp="0.25"/>&#xB1;<ce:hsp sp="0.25"/>5%, 38<ce:hsp sp="0.25"/>&#xB1;<ce:hsp sp="0.25"/>10%, 88<ce:hsp sp="0.25"/>&#xB1;<ce:hsp sp="0.25"/>2% of reduction vs. LPS-treated cells without compounds, respectively, <ce:italic>P</ce:italic><ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.01) (<ce:cross-ref refid="fig3">Fig. 3</ce:cross-ref><ce:float-anchor refid="fig3"/>A, upper). Consequently, IL-1&#x3B2; concentration in the media was markedly decreased (inhibitor A; 34<ce:hsp sp="0.25"/>&#xB1;<ce:hsp sp="0.25"/>10%, CBX; 75<ce:hsp sp="0.25"/>&#xB1;<ce:hsp sp="0.25"/>3% of reduction vs. LPS-treated cells, respectively, <ce:italic>P</ce:italic><ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.01) (<ce:cross-ref refid="fig3">Fig. 3</ce:cross-ref>A, lower). TNF-&#x3B1; mRNA (inhibitor B; 20<ce:hsp sp="0.25"/>&#xB1;<ce:hsp sp="0.25"/>11.7% [<ce:italic>P</ce:italic><ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.05], CBX; 34<ce:hsp sp="0.25"/>&#xB1;<ce:hsp sp="0.25"/>5% [<ce:italic>P</ce:italic><ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.01] of reduction vs. LPS-treated cells, respectively) (<ce:cross-ref refid="fig3">Fig. 3</ce:cross-ref>B, upper) and its concentration in the media (inhibitor B: 41<ce:hsp sp="0.25"/>&#xB1;<ce:hsp sp="0.25"/>8%, CBX: 57<ce:hsp sp="0.25"/>&#xB1;<ce:hsp sp="0.25"/>4% of reduction vs. LPS-treated cells, respectively, <ce:italic>P</ce:italic><ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.01) (<ce:cross-ref refid="fig3">Fig. 3</ce:cross-ref>B, lower) were also significantly suppressed by the treatment of 11&#x3B2;-HSD1 inhibitors. In MCP-1, only CBX exerted significant effect on the mRNA level (48<ce:hsp sp="0.25"/>&#xB1;<ce:hsp sp="0.25"/>11% of reduction vs. LPS-treated cells. <ce:italic>P</ce:italic><ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.01) (<ce:cross-ref refid="fig3">Fig. 3</ce:cross-ref>C, upper) and concentration in the media (57<ce:hsp sp="0.25"/>&#xB1;<ce:hsp sp="0.25"/>4% of reduction vs. LPS-treated cells. <ce:italic>P</ce:italic><ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.01) (<ce:cross-ref refid="fig3">Fig. 3</ce:cross-ref>C, lower).</ce:para> <ce:para>The mRNA level of IL1R1 (receptor for IL-1&#x3B2;), TNFR1 (receptor for TNF-&#x3B1;), CCR2 (receptor for MCP-1), toll-like receptor 4 (TLR4) (receptor for LPS) and GR (receptor for glucocorticoid) was not significantly changed with these 11&#x3B2;-HSD1 inhibitors (data not shown).</ce:para> </ce:section> <ce:section> <ce:label>3.3</ce:label> <ce:section-title>Effect of dexamethasone on inflammatory properties in J774.1 macrophages</ce:section-title> <ce:para>We examined the effect of glucocorticoid replenishment on the secretion of pro-inflammatory cytokine and chemokine in J774.1 macrophages. Treatment of J774.1 cells with dexamethasone (DEX) (10<ce:sup>&#x2212;10</ce:sup>&#x2013;10<ce:sup>&#x2212;7</ce:sup><ce:hsp sp="0.25"/>M, 24<ce:hsp sp="0.25"/>h) suppressed the mRNA expression and secretion of IL-1&#x3B2;, TNF&#x3B1; and MCP-1 in a dose-dependent manner (<ce:cross-ref refid="app1">supplementary figure A&#x2013;F</ce:cross-ref>). Furthermore, co-treatment of LPS (10<ce:hsp sp="0.25"/>ng/ml) with DEX markedly reduced the expression and secretion of IL-1&#x3B2;, TNF&#x3B1; and MCP-1 dose-dependently (<ce:cross-ref refid="app1">supplementary figure A&#x2013;F</ce:cross-ref>).</ce:para> <ce:para>Treatment of J774.1 cells with DEX (10<ce:sup>&#x2212;7</ce:sup> M) reduced IL-1&#x3B2; mRNA level (85<ce:hsp sp="0.25"/>&#xB1;<ce:hsp sp="0.25"/>8% of reduction vs. vehicle, 91<ce:hsp sp="0.25"/>&#xB1;<ce:hsp sp="0.25"/>0.1% of reduction vs. LPS-treated cells, respectively, <ce:italic>P</ce:italic><ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.01). Consequently, IL-1&#x3B2; concentration in the media was decreased (83<ce:hsp sp="0.25"/>&#xB1;<ce:hsp sp="0.25"/>8% of reduction vs. LPS-treated cells, <ce:italic>P</ce:italic><ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.01) (<ce:cross-ref refid="app1">supplementary figure A, D</ce:cross-ref>). Regarding TNF-&#x3B1;, mRNA (55<ce:hsp sp="0.25"/>&#xB1;<ce:hsp sp="0.25"/>8% of reduction vs. vehicle, 47<ce:hsp sp="0.25"/>&#xB1;<ce:hsp sp="0.25"/>14% of reduction vs. LPS-treated cells, respectively, <ce:italic>P</ce:italic><ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.01) and concentration in the media (51<ce:hsp sp="0.25"/>&#xB1;<ce:hsp sp="0.25"/>14% of reduction vs. vehicle, 43<ce:hsp sp="0.25"/>&#xB1;<ce:hsp sp="0.25"/>8% of reduction vs. LPS-treated cells, respectively, <ce:italic>P</ce:italic><ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.01) were markedly suppressed by DEX (<ce:cross-ref refid="app1">supplementary figure B, E</ce:cross-ref>). Regarding MCP-1, DEX also decreased the mRNA level (65<ce:hsp sp="0.25"/>&#xB1;<ce:hsp sp="0.25"/>4% of reduction vs. vehicle [<ce:italic>P</ce:italic><ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.05], 83<ce:hsp sp="0.25"/>&#xB1;<ce:hsp sp="0.25"/>3% of reduction vs. LPS-treated cells [<ce:italic>P</ce:italic><ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.01], respectively) and concentration in the media (81<ce:hsp sp="0.25"/>&#xB1;<ce:hsp sp="0.25"/>10% of reduction vs. vehicle, 68<ce:hsp sp="0.25"/>&#xB1;<ce:hsp sp="0.25"/>5% of reduction vs. LPS-treated cells, respectively, <ce:italic>P</ce:italic><ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.01) (<ce:cross-ref refid="app1">supplementary figure C, F</ce:cross-ref>).</ce:para> </ce:section> </ce:section> <ce:section> <ce:label>4</ce:label> <ce:section-title>Discussion</ce:section-title> <ce:para>Here, we demonstrated that J774.1 macrophages expressed considerable amount of mRNA and reductase activity of 11&#x3B2;-HSD1. Our data is the first to demonstrate that the cell activation with LPS markedly augmented mRNA expression and reductase activity of 11&#x3B2;-HSD1, accompanied by a drastic morphological change and increased secretion of pro-inflammatory cytokines <ce:cross-ref refid="bib13">[13]</ce:cross-ref>. Recent studies highlighted the concept that not only LPS but non-microbial molecules such as fatty acids can also activate macrophages through TLR4 <ce:cross-ref refid="bib21">[21]</ce:cross-ref>. It is also suggested that endogenous, intestine-derived LPS contributes to the pathophysiology of obesity-associated fatty liver diseases <ce:cross-ref refid="bib22">[22]</ce:cross-ref>. In this context, potential mechanism of LPS-mediated dysfunction of adipose tissue stimulates much interest in future studies.</ce:para> <ce:para>Glucocorticoids are widely used as anti-inflammatory agents in human clinics <ce:cross-ref refid="bib23">[23]</ce:cross-ref>. Consistent with the notion that glucocorticoids act as anti-inflammatory hormones, our data demonstrated that treatment of J774.1 cells with dexamethasone significantly suppressed the mRNA expression and secretion of IL-1&#x3B2;, TNF-&#x3B1; and MCP-1 in a dose-dependent manner (<ce:cross-ref refid="app1">supplementary figure</ce:cross-ref>). On the other hand, physiological effects of endogenous glucocorticoids are distinct from those in pharmacological or therapeutic concentrations of synthetic cortisol analogues <ce:cross-refs refid="bib24 bib25 bib26 bib27">[24&#x2013;27]</ce:cross-refs>. A recent study showed that 11&#x3B2;-HSD1-mediated intracellular glucocorticoid reamplification in macrophages enhanced phagocytic activity <ce:cross-ref refid="bib28">[28]</ce:cross-ref>. However, it still remains controversial whether the activation of 11&#x3B2;-HSD1 is involved in pro-inflammatory properties of macrophages. To test the possibility, we assessed the potential impact of pharmacological inhibition of 11&#x3B2;-HSD1 on secretion of pro-inflammatory cytokine and chemokine. Our data demonstrated for the first time that treatment of J774.1 cells with three structurally distinct 11&#x3B2;-HSD1 inhibitors considerably suppressed the mRNA expression and secretion of IL-1&#x3B2;, TNF-&#x3B1; or MCP-1, clearly indicating that intracellular regeneration of active glucocorticoid via 11&#x3B2;-HSD1 does exert pro-inflammatory effects on activated macrophages. Taking structural and pharmacological differences of compounds into consideration, further investigation is required to reinforce the result.</ce:para> <ce:para>Macrophages play pathophysiologic roles in adipose dysfunction, arteriosclerosis <ce:cross-ref refid="bib16">[16]</ce:cross-ref> and inflammatory fatty liver diseases <ce:cross-ref refid="bib22">[22]</ce:cross-ref>. A recent study showed that pharmacologic inhibition of 11&#x3B2;-HSD1 ameliorated diabetes, dyslipidemia <ce:cross-ref refid="bib29">[29]</ce:cross-ref> and arteriosclerosis <ce:cross-ref refid="bib16">[16]</ce:cross-ref> in mouse models. It should also be noted that, reminiscent of adipocytes <ce:cross-ref refid="bib16">[16]</ce:cross-ref>. 11&#x3B2;-HSD1 expression and reductase activity is predominated in macrophages (<ce:cross-ref refid="fig1">Fig. 1</ce:cross-ref>), while that of 11&#x3B2;-HSD2 and dehydrogenase activity were not detected in our assays (data not shown). Taken together, our results suggest that 11&#x3B2;-HSD1 in activated macrophages may be a novel target for the treatment of metabolic diseases.</ce:para> <ce:para>In adipose tissue, 11&#x3B2;-HSD1 was expressed not only in mature adipocytes but also stromal vascular fraction (SVF) cells which include infiltrated macrophages <ce:cross-ref refid="bib30">[30]</ce:cross-ref>. Number of cells contained in SVF was estimated to be two-thirds of that in whole adipose tissue <ce:cross-ref refid="bib31">[31]</ce:cross-ref>. Our data in human adipose tissue biopsies also showed that SVF from adipose tissue expressed 11&#x3B2;-HSD1 to a considerable extent (approximately 20% of that in floating matured adipocytes) (Yasue, S. et al. manuscript in preparation). Thus, 11&#x3B2;-HSD1 in activated macrophages may play a role in the pathophysiology of adipose inflammation and dysfunction. Further investigations in vivo should validate this notion and may open a fresh avenue for molecular and cellular mechanism of adipose inflammation and dysfunction.</ce:para> </ce:section> </ce:sections> <ce:acknowledgment xmlns:ce="http://www.elsevier.com/xml/common/dtd"> <ce:section-title>Acknowledgements</ce:section-title> <ce:para>We thank Dr. Y. Tominaga and S. Yokota (Kaneka Co. Osaka, Japan) for valuable help in the microsome assay, Dr. M. Fujimoto for critical discussion, and Ms. S. Masumoto, K. Takahashi, S. Maki and M. Nagamoto for assistance. This work was supported in part by Grant-in-Aid for Scientific Research (B2; 16390267), (S2; 16109007), Grant-in-Aid for Scientific Research on Priority Areas (adipomics, 15081101), Grant-in-Aid for Research on Measures for Intractable Diseases (Health and Labor Science Research Grant), Research Grant from Special Coordination Funds for Promoting Science and Technology (JST), AstraZeneca International Research Grant, Takeda Medical Research Foundation, Smoking Research Foundation, Metabolic Syndrome Foundation and Setsuro Fujii Memorial Osaka Foundation for Promotion of Fundamental Medical Research.</ce:para> </ce:acknowledgment> <ce:appendices xmlns:ce="http://www.elsevier.com/xml/common/dtd"> <ce:section view="compact-standard"> <ce:label>Appendix A</ce:label> <ce:section-title>Supplementary data</ce:section-title> <ce:para>Supplementary data associated with this article can be found, in the online version, at <ce:inter-ref xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="doi:10.1016/j.febslet.2006.11.032" xlink:type="simple">doi:10.1016/j.febslet.2006.11.032</ce:inter-ref>.</ce:para> </ce:section> <ce:section view="extended" id="app1"> <ce:label>Appendix A</ce:label> <ce:section-title>Supplementary data</ce:section-title> <ce:para> <ce:display> <ce:figure> <ce:label>Supplementary figure</ce:label> <ce:caption> <ce:simple-para><ce:bold>Dexamethasone reduced IL-1</ce:bold>&#x3B2;<ce:bold>, TNF-</ce:bold>&#x3B1; <ce:bold>or MCP-1 expression in and secretion from J774.1 macrophages.</ce:bold> J774.1 cells were treated with dexamethasone (DEX) (10<ce:sup>&#x2212;10</ce:sup>&#x2013;10<ce:sup>&#x2212;7</ce:sup> M) and LPS (10<ce:hsp sp="0.25"/>ng/ml) for 24<ce:hsp sp="0.25"/>h. [<ce:bold><ce:italic>upper</ce:italic></ce:bold>]; mRNA for (A-1) (A-2; left half of A-1) IL-1&#x3B2;, (B) TNF-&#x3B1; and (C) MCP-1 determined by real-time PCR. Level of each mRNA was normalized to that of 18<ce:hsp sp="0.25"/>S rRNA and expressed as a relative value vs. control. [<ce:bold><ce:italic>lower</ce:italic></ce:bold>]; Concentrations of (D) IL-1&#x3B2;, (E) TNF-&#x3B1; and (F) MCP-1<ce:hsp sp="0.25"/>in the media measured by ELISA. Data are expressed as mean &#xB1;S.E.M. of triplicate experiments. <ce:sup loc="pre">&#x2217;</ce:sup>P<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.05, <ce:sup loc="pre">&#x2217;&#x2217;</ce:sup>P<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.01 vs. vehicle (V) treated group. <ce:sup loc="pre">#</ce:sup>P<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.05, <ce:sup loc="pre">##</ce:sup>P<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.01 vs. LPS - treated cells.</ce:simple-para> </ce:caption> <ce:link locator="fx1"/> </ce:figure> </ce:display> </ce:para> </ce:section> </ce:appendices> </body> <tail> <ce:bibliography xmlns:ce="http://www.elsevier.com/xml/common/dtd"> <ce:section-title>References</ce:section-title> <ce:bibliography-sec> <ce:bib-reference id="bib1"> <ce:label>[1]</ce:label> <sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"> <sb:contribution> <sb:authors> <sb:author> <ce:given-name>E.S.</ce:given-name> <ce:surname>Ford</ce:surname> </sb:author> <sb:author> <ce:given-name>W.H.</ce:given-name> <ce:surname>Giles</ce:surname> </sb:author> <sb:author> <ce:given-name>W.H.</ce:given-name> <ce:surname>Dietz</ce:surname> </sb:author> </sb:authors> <sb:title> <sb:maintitle>Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey</sb:maintitle> </sb:title> </sb:contribution> <sb:host> <sb:issue> <sb:series> <sb:title> <sb:maintitle>Jama</sb:maintitle> </sb:title> <sb:volume-nr>287</sb:volume-nr> </sb:series> <sb:date>2002</sb:date> </sb:issue> <sb:pages> <sb:first-page>356</sb:first-page> <sb:last-page>359</sb:last-page> </sb:pages> </sb:host> </sb:reference> </ce:bib-reference> <ce:bib-reference id="bib2"> <ce:label>[2]</ce:label> <sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"> <sb:contribution> <sb:authors> <sb:author> <ce:given-name>I.J.</ce:given-name> <ce:surname>Bujalska</ce:surname> </sb:author> <sb:author> <ce:given-name>S.</ce:given-name> <ce:surname>Kumar</ce:surname> </sb:author> <sb:author> <ce:given-name>P.M.</ce:given-name> <ce:surname>Stewart</ce:surname> </sb:author> </sb:authors> <sb:title> <sb:maintitle>Does central obesity reflect &#x201C;Cushing&#x2019;s disease of the omentum?</sb:maintitle> </sb:title> </sb:contribution> <sb:host> <sb:issue> <sb:series> <sb:title> <sb:maintitle>Lancet</sb:maintitle> </sb:title> <sb:volume-nr>349</sb:volume-nr> </sb:series> <sb:date>1997</sb:date> </sb:issue> <sb:pages> <sb:first-page>1210</sb:first-page> <sb:last-page>1213</sb:last-page> </sb:pages> </sb:host> </sb:reference> </ce:bib-reference> <ce:bib-reference id="bib3"> <ce:label>[3]</ce:label> <sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"> <sb:contribution> <sb:authors> <sb:author> <ce:given-name>P.M.</ce:given-name> <ce:surname>Jamieson</ce:surname> </sb:author> <sb:author> <ce:given-name>K.E.</ce:given-name> <ce:surname>Chapman</ce:surname> </sb:author> <sb:author> <ce:given-name>C.R.</ce:given-name> <ce:surname>Edwards</ce:surname> </sb:author> <sb:author> <ce:given-name>J.R.</ce:given-name> <ce:surname>Seckl</ce:surname> </sb:author> </sb:authors> <sb:title> <sb:maintitle>11&#x3B2;-hydroxysteroid dehydrogenase is an exclusive 11 beta-reductase in primary cultures of rat hepatocytes: effect of physicochemical and hormonal manipulations</sb:maintitle> </sb:title> </sb:contribution> <sb:host> <sb:issue> <sb:series> <sb:title> <sb:maintitle>Endocrinology</sb:maintitle> </sb:title> <sb:volume-nr>136</sb:volume-nr> </sb:series> <sb:date>1995</sb:date> </sb:issue> <sb:pages> <sb:first-page>4754</sb:first-page> <sb:last-page>4761</sb:last-page> </sb:pages> </sb:host> </sb:reference> </ce:bib-reference> <ce:bib-reference id="bib4"> <ce:label>[4]</ce:label> <sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"> <sb:contribution> <sb:authors> <sb:author> <ce:given-name>D.J.</ce:given-name> <ce:surname>Wake</ce:surname> </sb:author> <sb:author> <ce:given-name>B.R.</ce:given-name> <ce:surname>Walker</ce:surname> </sb:author> </sb:authors> <sb:title> <sb:maintitle>11 beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome</sb:maintitle> </sb:title> </sb:contribution> <sb:host> <sb:issue> <sb:series> <sb:title> <sb:maintitle>Mol. Cell Endocrinol.</sb:maintitle> </sb:title> <sb:volume-nr>215</sb:volume-nr> </sb:series> <sb:date>2004</sb:date> </sb:issue> <sb:pages> <sb:first-page>45</sb:first-page> <sb:last-page>54</sb:last-page> </sb:pages> </sb:host> </sb:reference> </ce:bib-reference> <ce:bib-reference id="bib5"> <ce:label>[5]</ce:label> <sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"> <sb:contribution> <sb:authors> <sb:author> <ce:given-name>H.</ce:given-name> <ce:surname>Masuzaki</ce:surname> </sb:author> <sb:author> <ce:given-name>J.</ce:given-name> <ce:surname>Paterson</ce:surname> </sb:author> <sb:author> <ce:given-name>H.</ce:given-name> <ce:surname>Shinyama</ce:surname> </sb:author> <sb:author> <ce:given-name>N.M.</ce:given-name> <ce:surname>Morton</ce:surname> </sb:author> <sb:author> <ce:given-name>J.J.</ce:given-name> <ce:surname>Mullins</ce:surname> </sb:author> <sb:author> <ce:given-name>J.R.</ce:given-name> <ce:surname>Seckl</ce:surname> </sb:author> <sb:author> <ce:given-name>J.S.</ce:given-name> <ce:surname>Flier</ce:surname> </sb:author> </sb:authors> <sb:title> <sb:maintitle>A transgenic model of visceral obesity and the metabolic syndrome</sb:maintitle> </sb:title> </sb:contribution> <sb:host> <sb:issue> <sb:series> <sb:title> <sb:maintitle>Science</sb:maintitle> </sb:title> <sb:volume-nr>294</sb:volume-nr> </sb:series> <sb:date>2001</sb:date> </sb:issue> <sb:pages> <sb:first-page>2166</sb:first-page> <sb:last-page>2170</sb:last-page> </sb:pages> </sb:host> </sb:reference> </ce:bib-reference> <ce:bib-reference id="bib6"> <ce:label>[6]</ce:label> <sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"> <sb:contribution> <sb:authors> <sb:author> <ce:given-name>H.</ce:given-name> <ce:surname>Masuzaki</ce:surname> </sb:author> <sb:et-al/> </sb:authors> <sb:title> <sb:maintitle>Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice</sb:maintitle> </sb:title> </sb:contribution> <sb:host> <sb:issue> <sb:series> <sb:title> <sb:maintitle>J. Clin. Invest.</sb:maintitle> </sb:title> <sb:volume-nr>112</sb:volume-nr> </sb:series> <sb:date>2003</sb:date> </sb:issue> <sb:pages> <sb:first-page>83</sb:first-page> <sb:last-page>90</sb:last-page> </sb:pages> </sb:host> </sb:reference> </ce:bib-reference> <ce:bib-reference id="bib7"> <ce:label>[7]</ce:label> <sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"> <sb:contribution> <sb:authors> <sb:author> <ce:given-name>N.M.</ce:given-name> <ce:surname>Morton</ce:surname> </sb:author> <sb:et-al/> </sb:authors> <sb:title> <sb:maintitle>Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice</sb:maintitle> </sb:title> </sb:contribution> <sb:host> <sb:issue> <sb:series> <sb:title> <sb:maintitle>Diabetes</sb:maintitle> </sb:title> <sb:volume-nr>53</sb:volume-nr> </sb:series> <sb:date>2004</sb:date> </sb:issue> <sb:pages> <sb:first-page>931</sb:first-page> <sb:last-page>938</sb:last-page> </sb:pages> </sb:host> </sb:reference> </ce:bib-reference> <ce:bib-reference id="bib8"> <ce:label>[8]</ce:label> <sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"> <sb:contribution> <sb:authors> <sb:author> <ce:given-name>Y.</ce:given-name> <ce:surname>Kotelevtsev</ce:surname> </sb:author> <sb:et-al/> </sb:authors> <sb:title> <sb:maintitle>11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress</sb:maintitle> </sb:title> </sb:contribution> <sb:host> <sb:issue> <sb:series> <sb:title> <sb:maintitle>Proc. Natl. Acad. Sci. USA</sb:maintitle> </sb:title> <sb:volume-nr>94</sb:volume-nr> </sb:series> <sb:date>1997</sb:date> </sb:issue> <sb:pages> <sb:first-page>14924</sb:first-page> <sb:last-page>14929</sb:last-page> </sb:pages> </sb:host> </sb:reference> </ce:bib-reference> <ce:bib-reference id="bib9"> <ce:label>[9]</ce:label> <sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"> <sb:contribution> <sb:authors> <sb:author> <ce:given-name>H.J.</ce:given-name> <ce:surname>Harris</ce:surname> </sb:author> <sb:author> <ce:given-name>Y.</ce:given-name> <ce:surname>Kotelevtsev</ce:surname> </sb:author> <sb:author> <ce:given-name>J.J.</ce:given-name> <ce:surname>Mullins</ce:surname> </sb:author> <sb:author> <ce:given-name>J.R.</ce:given-name> <ce:surname>Seckl</ce:surname> </sb:author> <sb:author> <ce:given-name>M.C.</ce:given-name> <ce:surname>Holmes</ce:surname> </sb:author> </sb:authors> <sb:title> <sb:maintitle>Intracellular regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase (11beta-HSD)-1 plays a key role in regulation of the hypothalamic-pituitary-adrenal axis: analysis of 11beta-HSD-1-deficient mice</sb:maintitle> </sb:title> </sb:contribution> <sb:host> <sb:issue> <sb:series> <sb:title> <sb:maintitle>Endocrinology</sb:maintitle> </sb:title> <sb:volume-nr>142</sb:volume-nr> </sb:series> <sb:date>2001</sb:date> </sb:issue> <sb:pages> <sb:first-page>114</sb:first-page> <sb:last-page>120</sb:last-page> </sb:pages> </sb:host> </sb:reference> </ce:bib-reference> <ce:bib-reference id="bib10"> <ce:label>[10]</ce:label> <sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"> <sb:contribution> <sb:authors> <sb:author> <ce:given-name>S.P.</ce:given-name> <ce:surname>Weisberg</ce:surname> </sb:author> <sb:author> <ce:given-name>D.</ce:given-name> <ce:surname>McCann</ce:surname> </sb:author> <sb:author> <ce:given-name>M.</ce:given-name> <ce:surname>Desai</ce:surname> </sb:author> <sb:author> <ce:given-name>M.</ce:given-name> <ce:surname>Rosenbaum</ce:surname> </sb:author> <sb:author> <ce:given-name>R.L.</ce:given-name> <ce:surname>Leibel</ce:surname> </sb:author> <sb:author> <ce:given-name>A.W.</ce:given-name> <ce:surname>Ferrante</ce:surname> <ce:suffix>Jr.</ce:suffix> </sb:author> </sb:authors> <sb:title> <sb:maintitle>Obesity is associated with macrophage accumulation in adipose tissue</sb:maintitle> </sb:title> </sb:contribution> <sb:host> <sb:issue> <sb:series> <sb:title> <sb:maintitle>J. Clin. Invest.</sb:maintitle> </sb:title> <sb:volume-nr>112</sb:volume-nr> </sb:series> <sb:date>2003</sb:date> </sb:issue> <sb:pages> <sb:first-page>1796</sb:first-page> <sb:last-page>1808</sb:last-page> </sb:pages> </sb:host> </sb:reference> </ce:bib-reference> <ce:bib-reference id="bib11"> <ce:label>[11]</ce:label> <sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"> <sb:contribution> <sb:authors> <sb:author> <ce:given-name>H.</ce:given-name> <ce:surname>Xu</ce:surname> </sb:author> <sb:et-al/> </sb:authors> <sb:title> <sb:maintitle>Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance</sb:maintitle> </sb:title> </sb:contribution> <sb:host> <sb:issue> <sb:series> <sb:title> <sb:maintitle>J. Clin. Invest.</sb:maintitle> </sb:title> <sb:volume-nr>112</sb:volume-nr> </sb:series> <sb:date>2003</sb:date> </sb:issue> <sb:pages> <sb:first-page>1821</sb:first-page> <sb:last-page>1830</sb:last-page> </sb:pages> </sb:host> </sb:reference> </ce:bib-reference> <ce:bib-reference id="bib12"> <ce:label>[12]</ce:label> <sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"> <sb:contribution> <sb:authors> <sb:author> <ce:given-name>T.</ce:given-name> <ce:surname>Suganami</ce:surname> </sb:author> <sb:author> <ce:given-name>J.</ce:given-name> <ce:surname>Nishida</ce:surname> </sb:author> <sb:author> <ce:given-name>Y.</ce:given-name> <ce:surname>Ogawa</ce:surname> </sb:author> </sb:authors> <sb:title> <sb:maintitle>A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha</sb:maintitle> </sb:title> </sb:contribution> <sb:host> <sb:issue> <sb:series> <sb:title> <sb:maintitle>Arterioscler. Thromb. Vasc. Biol.</sb:maintitle> </sb:title> <sb:volume-nr>25</sb:volume-nr> </sb:series> <sb:date>2005</sb:date> </sb:issue> <sb:pages> <sb:first-page>2062</sb:first-page> <sb:last-page>2068</sb:last-page> </sb:pages> </sb:host> </sb:reference> </ce:bib-reference> <ce:bib-reference id="bib13"> <ce:label>[13]</ce:label> <sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"> <sb:contribution> <sb:authors> <sb:author> <ce:given-name>P.</ce:given-name> <ce:surname>Ralph</ce:surname> </sb:author> <sb:author> <ce:given-name>I.</ce:given-name> <ce:surname>Nakoinz</ce:surname> </sb:author> </sb:authors> <sb:title> <sb:maintitle>Phagocytosis and cytolysis by a macrophage tumour and its cloned cell line</sb:maintitle> </sb:title> </sb:contribution> <sb:host> <sb:issue> <sb:series> <sb:title> <sb:maintitle>Nature</sb:maintitle> </sb:title> <sb:volume-nr>257</sb:volume-nr> </sb:series> <sb:date>1975</sb:date> </sb:issue> <sb:pages> <sb:first-page>393</sb:first-page> <sb:last-page>394</sb:last-page> </sb:pages> </sb:host> </sb:reference> </ce:bib-reference> <ce:bib-reference id="bib14"> <ce:label>[14]</ce:label> <sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"> <sb:contribution> <sb:authors> <sb:author> <ce:given-name>R.C.</ce:given-name> <ce:surname>Andrews</ce:surname> </sb:author> <sb:author> <ce:given-name>O.</ce:given-name> <ce:surname>Rooyackers</ce:surname> </sb:author> <sb:author> <ce:given-name>B.R.</ce:given-name> <ce:surname>Walker</ce:surname> </sb:author> </sb:authors> <sb:title> <sb:maintitle>Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes</sb:maintitle> </sb:title> </sb:contribution> <sb:host> <sb:issue> <sb:series> <sb:title> <sb:maintitle>J. Clin. Endocrinol. Metab.</sb:maintitle> </sb:title> <sb:volume-nr>88</sb:volume-nr> </sb:series> <sb:date>2003</sb:date> </sb:issue> <sb:pages> <sb:first-page>285</sb:first-page> <sb:last-page>291</sb:last-page> </sb:pages> </sb:host> </sb:reference> </ce:bib-reference> <ce:bib-reference id="bib15"> <ce:label>[15]</ce:label> <sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"> <sb:contribution> <sb:authors> <sb:author> <ce:given-name>T.C.</ce:given-name> <ce:surname>Sandeep</ce:surname> </sb:author> <sb:author> <ce:given-name>R.</ce:given-name> <ce:surname>Andrew</ce:surname> </sb:author> <sb:author> <ce:given-name>N.Z.</ce:given-name> <ce:surname>Homer</ce:surname> </sb:author> <sb:author> <ce:given-name>R.C.</ce:given-name> <ce:surname>Andrews</ce:surname> </sb:author> <sb:author> <ce:given-name>K.</ce:given-name> <ce:surname>Smith</ce:surname> </sb:author> <sb:author> <ce:given-name>B.R.</ce:given-name> <ce:surname>Walker</ce:surname> </sb:author> </sb:authors> <sb:title> <sb:maintitle>Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone</sb:maintitle> </sb:title> </sb:contribution> <sb:host> <sb:issue> <sb:series> <sb:title> <sb:maintitle>Diabetes</sb:maintitle> </sb:title> <sb:volume-nr>54</sb:volume-nr> </sb:series> <sb:date>2005</sb:date> </sb:issue> <sb:pages> <sb:first-page>872</sb:first-page> <sb:last-page>879</sb:last-page> </sb:pages> </sb:host> </sb:reference> </ce:bib-reference> <ce:bib-reference id="bib16"> <ce:label>[16]</ce:label> <sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"> <sb:contribution> <sb:authors> <sb:author> <ce:given-name>A.</ce:given-name> <ce:surname>Hermanowski-Vosatka</ce:surname> </sb:author> <sb:et-al/> </sb:authors> <sb:title> <sb:maintitle>11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice</sb:maintitle> </sb:title> </sb:contribution> <sb:host> <sb:issue> <sb:series> <sb:title> <sb:maintitle>J. Exp. Med.</sb:maintitle> </sb:title> <sb:volume-nr>202</sb:volume-nr> </sb:series> <sb:date>2005</sb:date> </sb:issue> <sb:pages> <sb:first-page>517</sb:first-page> <sb:last-page>527</sb:last-page> </sb:pages> </sb:host> </sb:reference> </ce:bib-reference> <ce:bib-reference id="bib17"> <ce:label>[17]</ce:label> <sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"> <sb:contribution> <sb:authors> <sb:author> <ce:given-name>M.</ce:given-name> <ce:surname>Hult</ce:surname> </sb:author> <sb:et-al/> </sb:authors> <sb:title> <sb:maintitle>Active site variability of type 1 11beta-hydroxysteroid dehydrogenase revealed by selective inhibitors and cross-species comparisons</sb:maintitle> </sb:title> </sb:contribution> <sb:host> <sb:issue> <sb:series> <sb:title> <sb:maintitle>Mol. Cell Endocrinol.</sb:maintitle> </sb:title> <sb:volume-nr>248</sb:volume-nr> </sb:series> <sb:date>2006</sb:date> </sb:issue> <sb:pages> <sb:first-page>26</sb:first-page> <sb:last-page>33</sb:last-page> </sb:pages> </sb:host> </sb:reference> </ce:bib-reference> <ce:bib-reference id="bib18"> <ce:label>[18]</ce:label> <sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"> <sb:contribution> <sb:authors> <sb:author> <ce:given-name>S.J.</ce:given-name> <ce:surname>Wang</ce:surname> </sb:author> <sb:et-al/> </sb:authors> <sb:title> <sb:maintitle>Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 reduces food intake and weight gain but maintains energy expenditure in diet-induced obese mice</sb:maintitle> </sb:title> </sb:contribution> <sb:host> <sb:issue> <sb:series> <sb:title> <sb:maintitle>Diabetologia</sb:maintitle> </sb:title> <sb:volume-nr>49</sb:volume-nr> </sb:series> <sb:date>2006</sb:date> </sb:issue> <sb:pages> <sb:first-page>1333</sb:first-page> <sb:last-page>1337</sb:last-page> </sb:pages> </sb:host> </sb:reference> </ce:bib-reference> <ce:bib-reference id="bib19"> <ce:label>[19]</ce:label> <sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"> <sb:contribution> <sb:authors> <sb:author> <ce:given-name>A.</ce:given-name> <ce:surname>Poltorak</ce:surname> </sb:author> <sb:et-al/> </sb:authors> <sb:title> <sb:maintitle>Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene</sb:maintitle> </sb:title> </sb:contribution> <sb:host> <sb:issue> <sb:series> <sb:title> <sb:maintitle>Science</sb:maintitle> </sb:title> <sb:volume-nr>282</sb:volume-nr> </sb:series> <sb:date>1998</sb:date> </sb:issue> <sb:pages> <sb:first-page>2085</sb:first-page> <sb:last-page>2088</sb:last-page> </sb:pages> </sb:host> </sb:reference> </ce:bib-reference> <ce:bib-reference id="bib20"> <ce:label>[20]</ce:label> <sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"> <sb:contribution> <sb:authors> <sb:author> <ce:given-name>K.</ce:given-name> <ce:surname>Hoshino</ce:surname> </sb:author> <sb:author> <ce:given-name>O.</ce:given-name> <ce:surname>Takeuchi</ce:surname> </sb:author> <sb:author> <ce:given-name>T.</ce:given-name> <ce:surname>Kawai</ce:surname> </sb:author> <sb:author> <ce:given-name>H.</ce:given-name> <ce:surname>Sanjo</ce:surname> </sb:author> <sb:author> <ce:given-name>T.</ce:given-name> <ce:surname>Ogawa</ce:surname> </sb:author> <sb:author> <ce:given-name>Y.</ce:given-name> <ce:surname>Takeda</ce:surname> </sb:author> <sb:author> <ce:given-name>K.</ce:given-name> <ce:surname>Takeda</ce:surname> </sb:author> <sb:author> <ce:given-name>S.</ce:given-name> <ce:surname>Akira</ce:surname> </sb:author> </sb:authors> <sb:title> <sb:maintitle>Cutting edge: toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product</sb:maintitle> </sb:title> </sb:contribution> <sb:host> <sb:issue> <sb:series> <sb:title> <sb:maintitle>J. Immunol.</sb:maintitle> </sb:title> <sb:volume-nr>162</sb:volume-nr> </sb:series> <sb:date>1999</sb:date> </sb:issue> <sb:pages> <sb:first-page>3749</sb:first-page> <sb:last-page>3752</sb:last-page> </sb:pages> </sb:host> </sb:reference> </ce:bib-reference> <ce:bib-reference id="bib21"> <ce:label>[21]</ce:label> <sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"> <sb:contribution> <sb:authors> <sb:author> <ce:given-name>J.Y.</ce:given-name> <ce:surname>Lee</ce:surname> </sb:author> <sb:author> <ce:given-name>K.H.</ce:given-name> <ce:surname>Sohn</ce:surname> </sb:author> <sb:author> <ce:given-name>S.H.</ce:given-name> <ce:surname>Rhee</ce:surname> </sb:author> <sb:author> <ce:given-name>D.</ce:given-name> <ce:surname>Hwang</ce:surname> </sb:author> </sb:authors> <sb:title> <sb:maintitle>Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4</sb:maintitle> </sb:title> </sb:contribution> <sb:host> <sb:issue> <sb:series> <sb:title> <sb:maintitle>J. Biol. Chem.</sb:maintitle> </sb:title> <sb:volume-nr>276</sb:volume-nr> </sb:series> <sb:date>2001</sb:date> </sb:issue> <sb:pages> <sb:first-page>16683</sb:first-page> <sb:last-page>16689</sb:last-page> </sb:pages> </sb:host> </sb:reference> </ce:bib-reference> <ce:bib-reference id="bib22"> <ce:label>[22]</ce:label> <sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"> <sb:contribution> <sb:authors> <sb:author> <ce:given-name>S.Q.</ce:given-name> <ce:surname>Yang</ce:surname> </sb:author> <sb:author> <ce:given-name>H.Z.</ce:given-name> <ce:surname>Lin</ce:surname> </sb:author> <sb:author> <ce:given-name>M.D.</ce:given-name> <ce:surname>Lane</ce:surname> </sb:author> <sb:author> <ce:given-name>M.</ce:given-name> <ce:surname>Clemens</ce:surname> </sb:author> <sb:author> <ce:given-name>A.M.</ce:given-name> <ce:surname>Diehl</ce:surname> </sb:author> </sb:authors> <sb:title> <sb:maintitle>Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis</sb:maintitle> </sb:title> </sb:contribution> <sb:host> <sb:issue> <sb:series> <sb:title> <sb:maintitle>Proc. Natl. Acad. Sci. USA</sb:maintitle> </sb:title> <sb:volume-nr>94</sb:volume-nr> </sb:series> <sb:date>1997</sb:date> </sb:issue> <sb:pages> <sb:first-page>2557</sb:first-page> <sb:last-page>2562</sb:last-page> </sb:pages> </sb:host> </sb:reference> </ce:bib-reference> <ce:bib-reference id="bib23"> <ce:label>[23]</ce:label> <sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"> <sb:contribution> <sb:authors> <sb:author> <ce:given-name>T.</ce:given-name> <ce:surname>Rhen</ce:surname> </sb:author> <sb:author> <ce:given-name>J.A.</ce:given-name> <ce:surname>Cidlowski</ce:surname> </sb:author> </sb:authors> <sb:title> <sb:maintitle>Antiinflammatory action of glucocorticoids &#x2013; new mechanisms for old drugs</sb:maintitle> </sb:title> </sb:contribution> <sb:host> <sb:issue> <sb:series> <sb:title> <sb:maintitle>N. Engl. J. Med.</sb:maintitle> </sb:title> <sb:volume-nr>353</sb:volume-nr> </sb:series> <sb:date>2005</sb:date> </sb:issue> <sb:pages> <sb:first-page>1711</sb:first-page> <sb:last-page>1723</sb:last-page> </sb:pages> </sb:host> </sb:reference> </ce:bib-reference> <ce:bib-reference id="bib24"> <ce:label>[24]</ce:label> <sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"> <sb:contribution> <sb:authors> <sb:author> <ce:given-name>A.E.</ce:given-name> <ce:surname>Barber</ce:surname> </sb:author> <sb:author> <ce:given-name>S.M.</ce:given-name> <ce:surname>Coyle</ce:surname> </sb:author> <sb:author> <ce:given-name>M.A.</ce:given-name> <ce:surname>Marano</ce:surname> </sb:author> <sb:author> <ce:given-name>E.</ce:given-name> <ce:surname>Fischer</ce:surname> </sb:author> <sb:author> <ce:given-name>S.E.</ce:given-name> <ce:surname>Calvano</ce:surname> </sb:author> <sb:author> <ce:given-name>Y.</ce:given-name> <ce:surname>Fong</ce:surname> </sb:author> <sb:author> <ce:given-name>L.L.</ce:given-name> <ce:surname>Moldawer</ce:surname> </sb:author> <sb:author> <ce:given-name>S.F.</ce:given-name> <ce:surname>Lowry</ce:surname> </sb:author> </sb:authors> <sb:title> <sb:maintitle>Glucocorticoid therapy alters hormonal and cytokine responses to endotoxin in man</sb:maintitle> </sb:title> </sb:contribution> <sb:host> <sb:issue> <sb:series> <sb:title> <sb:maintitle>J. Immunol.</sb:maintitle> </sb:title> <sb:volume-nr>150</sb:volume-nr> </sb:series> <sb:date>1993</sb:date> </sb:issue> <sb:pages> <sb:first-page>1999</sb:first-page> <sb:last-page>2006</sb:last-page> </sb:pages> </sb:host> </sb:reference> </ce:bib-reference> <ce:bib-reference id="bib25"> <ce:label>[25]</ce:label> <sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"> <sb:contribution> <sb:authors> <sb:author> <ce:given-name>J.</ce:given-name> <ce:surname>Liao</ce:surname> </sb:author> <sb:author> <ce:given-name>J.A.</ce:given-name> <ce:surname>Keiser</ce:surname> </sb:author> <sb:author> <ce:given-name>W.E.</ce:given-name> <ce:surname>Scales</ce:surname> </sb:author> <sb:author> <ce:given-name>S.L.</ce:given-name> <ce:surname>Kunkel</ce:surname> </sb:author> <sb:author> <ce:given-name>M.J.</ce:given-name> <ce:surname>Kluger</ce:surname> </sb:author> </sb:authors> <sb:title> <sb:maintitle>Role of corticosterone in TNF and IL-6 production in isolated perfused rat liver</sb:maintitle> </sb:title> </sb:contribution> <sb:host> <sb:issue> <sb:series> <sb:title> <sb:maintitle>Am. J. Physiol.</sb:maintitle> </sb:title> <sb:volume-nr>268</sb:volume-nr> </sb:series> <sb:date>1995</sb:date> </sb:issue> <sb:pages> <sb:first-page>R699</sb:first-page> <sb:last-page>R706</sb:last-page> </sb:pages> </sb:host> </sb:reference> </ce:bib-reference> <ce:bib-reference id="bib26"> <ce:label>[26]</ce:label> <sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"> <sb:contribution> <sb:authors> <sb:author> <ce:given-name>R.M.</ce:given-name> <ce:surname>Sapolsky</ce:surname> </sb:author> <sb:author> <ce:given-name>L.M.</ce:given-name> <ce:surname>Romero</ce:surname> </sb:author> <sb:author> <ce:given-name>A.U.</ce:given-name> <ce:surname>Munck</ce:surname> </sb:author> </sb:authors> <sb:title> <sb:maintitle>How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions</sb:maintitle> </sb:title> </sb:contribution> <sb:host> <sb:issue> <sb:series> <sb:title> <sb:maintitle>Endocr. Rev.</sb:maintitle> </sb:title> <sb:volume-nr>21</sb:volume-nr> </sb:series> <sb:date>2000</sb:date> </sb:issue> <sb:pages> <sb:first-page>55</sb:first-page> <sb:last-page>89</sb:last-page> </sb:pages> </sb:host> </sb:reference> </ce:bib-reference> <ce:bib-reference id="bib27"> <ce:label>[27]</ce:label> <sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"> <sb:contribution> <sb:authors> <sb:author> <ce:given-name>G.P.</ce:given-name> <ce:surname>Smyth</ce:surname> </sb:author> <sb:author> <ce:given-name>P.P.</ce:given-name> <ce:surname>Stapleton</ce:surname> </sb:author> <sb:author> <ce:given-name>T.A.</ce:given-name> <ce:surname>Freeman</ce:surname> </sb:author> <sb:author> <ce:given-name>E.M.</ce:given-name> <ce:surname>Concannon</ce:surname> </sb:author> <sb:author> <ce:given-name>J.R.</ce:given-name> <ce:surname>Mestre</ce:surname> </sb:author> <sb:author> <ce:given-name>M.</ce:given-name> <ce:surname>Duff</ce:surname> </sb:author> <sb:author> <ce:given-name>S.</ce:given-name> <ce:surname>Maddali</ce:surname> </sb:author> <sb:author> <ce:given-name>J.M.</ce:given-name> <ce:surname>Daly</ce:surname> </sb:author> </sb:authors> <sb:title> <sb:maintitle>Glucocorticoid pretreatment induces cytokine overexpression and nuclear factor-kappaB activation in macrophages</sb:maintitle> </sb:title> </sb:contribution> <sb:host> <sb:issue> <sb:series> <sb:title> <sb:maintitle>J. Surg. Res.</sb:maintitle> </sb:title> <sb:volume-nr>116</sb:volume-nr> </sb:series> <sb:date>2004</sb:date> </sb:issue> <sb:pages> <sb:first-page>253</sb:first-page> <sb:last-page>261</sb:last-page> </sb:pages> </sb:host> </sb:reference> </ce:bib-reference> <ce:bib-reference id="bib28"> <ce:label>[28]</ce:label> <sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"> <sb:contribution> <sb:authors> <sb:author> <ce:given-name>J.S.</ce:given-name> <ce:surname>Gilmour</ce:surname> </sb:author> <sb:et-al/> </sb:authors> <sb:title> <sb:maintitle>Local amplification of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1 promotes macrophage phagocytosis of apoptotic leukocytes</sb:maintitle> </sb:title> </sb:contribution> <sb:host> <sb:issue> <sb:series> <sb:title> <sb:maintitle>J. Immunol.</sb:maintitle> </sb:title> <sb:volume-nr>176</sb:volume-nr> </sb:series> <sb:date>2006</sb:date> </sb:issue> <sb:pages> <sb:first-page>7605</sb:first-page> <sb:last-page>7611</sb:last-page> </sb:pages> </sb:host> </sb:reference> </ce:bib-reference> <ce:bib-reference id="bib29"> <ce:label>[29]</ce:label> <sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"> <sb:contribution> <sb:authors> <sb:author> <ce:given-name>P.</ce:given-name> <ce:surname>Alberts</ce:surname> </sb:author> <sb:et-al/> </sb:authors> <sb:title> <sb:maintitle>Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains</sb:maintitle> </sb:title> </sb:contribution> <sb:host> <sb:issue> <sb:series> <sb:title> <sb:maintitle>Endocrinology</sb:maintitle> </sb:title> <sb:volume-nr>144</sb:volume-nr> </sb:series> <sb:date>2003</sb:date> </sb:issue> <sb:pages> <sb:first-page>4755</sb:first-page> <sb:last-page>4762</sb:last-page> </sb:pages> </sb:host> </sb:reference> </ce:bib-reference> <ce:bib-reference id="bib30"> <ce:label>[30]</ce:label> <sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"> <sb:contribution> <sb:authors> <sb:author> <ce:given-name>O.</ce:given-name> <ce:surname>Paulmyer-Lacroix</ce:surname> </sb:author> <sb:author> <ce:given-name>S.</ce:given-name> <ce:surname>Boullu</ce:surname> </sb:author> <sb:author> <ce:given-name>C.</ce:given-name> <ce:surname>Oliver</ce:surname> </sb:author> <sb:author> <ce:given-name>M.C.</ce:given-name> <ce:surname>Alessi</ce:surname> </sb:author> <sb:author> <ce:given-name>M.</ce:given-name> <ce:surname>Grino</ce:surname> </sb:author> </sb:authors> <sb:title> <sb:maintitle>Expression of the mRNA coding for 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patients: an in situ hybridization study</sb:maintitle> </sb:title> </sb:contribution> <sb:host> <sb:issue> <sb:series> <sb:title> <sb:maintitle>J. Clin. Endocrinol. Metab.</sb:maintitle> </sb:title> <sb:volume-nr>87</sb:volume-nr> </sb:series> <sb:date>2002</sb:date> </sb:issue> <sb:pages> <sb:first-page>2701</sb:first-page> <sb:last-page>2705</sb:last-page> </sb:pages> </sb:host> </sb:reference> </ce:bib-reference> <ce:bib-reference id="bib31"> <ce:label>[31]</ce:label> <sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"> <sb:contribution> <sb:authors> <sb:author> <ce:given-name>M.</ce:given-name> <ce:surname>Rodbell</ce:surname> </sb:author> </sb:authors> <sb:title> <sb:maintitle>Localization of lipoprotein lipase in fat cells of rat adipose tissue</sb:maintitle> </sb:title> </sb:contribution> <sb:host> <sb:issue> <sb:series> <sb:title> <sb:maintitle>J. Biol. Chem.</sb:maintitle> </sb:title> <sb:volume-nr>239</sb:volume-nr> </sb:series> <sb:date>1964</sb:date> </sb:issue> <sb:pages> <sb:first-page>753</sb:first-page> <sb:last-page>755</sb:last-page> </sb:pages> </sb:host> </sb:reference> </ce:bib-reference> </ce:bibliography-sec> </ce:bibliography> </tail> </article>
